Home

Nature is the largest laboratory on planet Earth and Evolution is the biggest and longest running experiment. We can learn from it to develop innovative solution for a sustainable planet.

Pathogen Capture Technology (PCT)

Aquila Bioscience has developed a proprietary Pathogen Capture Technology (PCT) platform designed to capture and neutralise viruses, bacteria, and fungi by mimicking the natural binding structures pathogens use to infect cells.

This biomimetic approach creates a highly selective, Velcro-like binding mechanism that can be applied across multiple commercial formats and end markets. The platform is already being deployed through the ABD Device and ProShield Spray, with additional product and application opportunities in development.

Video Player

R&D

Aquila Bioscience is an innovative R&D company aiming to deliver disruptive technologies and sustainable solutions in carbohydrate based biology, and its applications in pathogen management.

References

Aquila Bioscience is heavily invested in scientific research and is busy discussing, presenting and writing about developments in green chemistry and glycoscience.

Next Gen Products

Carbohydrates (also called glycans) are universally present on every cell and are essential for cell-cell communication. Aquila Bioscience is at the forefront of applying glycoscience.

News/Media

Our mission is to protect the world’s health through developing technologically advanced and environmentally friendly products using nature based solutions.

Products

Aquila Bioscience creates innovative products free from alcohol, biocides and toxic chemicals and as so, do not cause skin irritation or destroy skin cells.

Shop

Based on its unique science, Aquila has released pilot products. Please inquire for further information.
Inquire

15

R&D Staff

200 M2

BioInnovation Space

€ 3.5 m

Research Funding

99 .9%

Effective Against SARS-CoV-2

Our products are shipped to clients globally.

MEDICAL RESEARCH 90%
BIOTECHNOLOGY 80%

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 959436

Website last updated in Feb 2025

Copyright © 2026 Aquila Bioscience. All rights reserved.